Kynurenine and uric acid levels in chronic myeloid leukemia patients

References

• Metz R, Duhadaway JB, Kamasani U, Laury-Kleintop L, Muller AJ, Prendergast GC. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res. 2007; 67:7082-7; PMID:17671174; http://dx.doi.org/10.1158/0008-5472.CAN-07-1872
   PubMed Web of Science ®Google Scholar
• Capece L, Arrar M, Roitberg AE, Yeh SR, Marti MA, Estrin DA. Substrate stereo-specificity in tryptophan dioxygenase and indoleamine 2,3-dioxygenase. Proteins 2010; 78:2961-72; PMID:20715188; http://dx.doi.org/10.1002/prot.22819
   PubMed Web of Science ®Google Scholar
• Brown RR, Ozaki Y, Datta SP, Borden EC, Sondel PM, Malone DG. Implications of interferon-induced tryptophan catabolism in cancer, auto-immune diseases and AIDS. Adv. Exp. Med. Biol. 1991; 294:425-35; PMID:1722946; http://dx.doi.org/10.1007/978-1-4684-5952-4_39
   PubMedGoogle Scholar
• Danesch U, Gloss B, Schmid W, Schutz G, Schule R, Renkawitz R. Glucocorticoid induction of the rat tryptophan oxygenase gene is mediated by two widely separated glucocorticoid-responsive elements. EMBO J. 1987; 6:625-30; PMID:3582368
   PubMed Web of Science ®Google Scholar
• Takikawa O, Yoshida R, Kido R, Hayaishi O. Tryptophan degradation in mice initiated by indoleamine 2,3-dioxygenase. J. Biol. Chem. 1986; 261:3648-53; PMID:2419335
   PubMed Web of Science ®Google Scholar
• Muller N, Schwarz MJ. Immune System and Schizophrenia. Curr. Immunol. Rev. 2010; 6:213-20; PMID:21057585; http://dx.doi.org/10.2174/157339510791823673
   PubMedGoogle Scholar
• Dankers AC, Mutsaers HA, Dijkman HB, van den Heuvel LP, Hoenderop JG, Sweep FC, Russel FG, Masereeuw R. Hyperuricemia influences tryptophan metabolism via inhibition of multidrug resistance protein 4 (MRP4) and breast cancer resistance protein (BCRP). Biochim. Biophys. Acta 2013; 1832:1715-22; PMID:23665398; http://dx.doi.org/10.1016/j.bbadis.2013.05.002
   PubMed Web of Science ®Google Scholar
• Mackenzie CR, Gonzalez RG, Kniep E, Roch S, Daubener W. Cytokine mediated regulation of interferon-gamma-induced IDO activation. Adv. Exp. Med. Biol. 1999; 467:533-9; PMID:10721097; http://dx.doi.org/10.1007/978-1-4615-4709-9_66
   PubMed Web of Science ®Google Scholar
• Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ, Marshall B, Brown C, Mellor AL. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998; 281:1191-3; PMID:9712583; http://dx.doi.org/10.1126/science.281.5380.1191
   PubMed Web of Science ®Google Scholar
• Blaschitz A, Gauster M, Fuchs D, Lang I, Maschke P, Ulrich D, Karpf E, Takikawa O, Schimek MG, Dohr G et al. Vascular endothelial expression of indoleamine 2,3-dioxygenase 1 forms a positive gradient towards the feto-maternal interface. PLoS. One. 2011; 6:e21774; PMID:21755000; http://dx.doi.org/10.1371/journal.pone.0021774
   PubMedGoogle Scholar
• Fallarino F, Volpi C, Zelante T, Vacca C, Calvitti M, Fioretti MC, Puccetti P, Romani L, Grohmann U. IDO mediates TLR9-driven protection from experimental autoimmune diabetes. J. Immunol. 2009; 183:6303-12; PMID:19841163; http://dx.doi.org/10.4049/jimmunol.0901577
   PubMed Web of Science ®Google Scholar
• Ozaki Y, Edelstein MP, Duch DS. Induction of indoleamine 2,3-dioxygenase: a mechanism of the antitumor activity of interferon gamma. Proc. Natl. Acad. Sci. U. S. A 1988; 85:1242-6; PMID:3124115; http://dx.doi.org/10.1073/pnas.85.4.1242
   PubMed Web of Science ®Google Scholar
• Fallarino F, Grohmann U, Hwang KW, Orabona C, Vacca C, Bianchi R, Belladonna ML, Fioretti MC, Alegre ML, Puccetti P. Modulation of tryptophan catabolism by regulatory T cells. Nat. Immunol. 2003; 4:1206-12; PMID:14578884; http://dx.doi.org/10.1038/ni1003
   PubMed Web of Science ®Google Scholar
• Prendergast GC. Immune escape as a fundamental trait of cancer: focus on IDO. Oncogene 2008; 27:3889-900; PMID:18317452; http://dx.doi.org/10.1038/onc.2008.35
   PubMed Web of Science ®Google Scholar
• Baban B, Chandler PR, Sharma MD, Pihkala J, Koni PA, Munn DH, Mellor AL. IDO activates regulatory T cells and blocks their conversion into Th17-like T cells. J. Immunol. 2009; 183:2475-83; PMID:19635913; http://dx.doi.org/10.4049/jimmunol.0900986
   PubMed Web of Science ®Google Scholar
• Mezrich JD, Fechner JH, Zhang X, Johnson BP, Burlingham WJ, Bradfield CA. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J. Immunol. 2010; 185:3190-8; PMID:20720200; http://dx.doi.org/10.4049/jimmunol.0903670
   PubMed Web of Science ®Google Scholar
• Munn DH. Indoleamine 2,3-dioxygenase, Tregs and cancer. Curr. Med. Chem. 2011; 18:2240-6; PMID:21517755; http://dx.doi.org/10.2174/092986711795656045
   PubMed Web of Science ®Google Scholar
• Fallarino F, Grohmann U, You S, McGrath BC, Cavener DR, Vacca C, Orabona C, Bianchi R, Belladonna ML, Volpi C et al. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J. Immunol. 2006; 176:6752-61; PMID:16709834; http://dx.doi.org/10.4049/jimmunol.176.11.6752
   PubMed Web of Science ®Google Scholar
• Mellor AL, Baban B, Chandler P, Marshall B, Jhaver K, Hansen A, Koni PA, Iwashima M, Munn DH. Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. J. Immunol. 2003; 171:1652-5; PMID:12902462; http://dx.doi.org/10.4049/jimmunol.171.4.1652
   PubMed Web of Science ®Google Scholar
• Fallarino F, Grohmann U, Vacca C, Bianchi R, Orabona C, Spreca A, Fioretti MC, Puccetti P. T cell apoptosis by tryptophan catabolism. Cell Death. Differ. 2002; 9:1069-77; PMID:12232795; http://dx.doi.org/10.1038/sj.cdd.4401073
   PubMed Web of Science ®Google Scholar
• Song H, Park H, Kim J, Park G, Kim YS, Kim SM, Kim D, Seo SK, Lee HK, Cho D et al. IDO metabolite produced by EBV-transformed B cells inhibits surface expression of NKG2D in NK cells via the c-Jun N-terminal kinase (JNK) pathway. Immunol. Lett. 2011; 136:187-93; PMID:21277902; http://dx.doi.org/10.1016/j.imlet.2011.01.009
   PubMed Web of Science ®Google Scholar
• Witkiewicz AK, Costantino CL, Metz R, Muller AJ, Prendergast GC, Yeo CJ, Brody JR. Genotyping and expression analysis of IDO2 in human pancreatic cancer: a novel, active target. J. Am. Coll. Surg. 2009; 208:781-7; PMID:19476837; http://dx.doi.org/10.1016/j.jamcollsurg.2008.12.018
   PubMed Web of Science ®Google Scholar
• Pilotte L, Larrieu P, Stroobant V, Colau D, Dolusic E, Frederick R, De PE, Uyttenhove C, Wouters J, Masereel B et al. Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase. Proc. Natl. Acad. Sci. U. S. A 2012; 109:2497-502; PMID:22308364; http://dx.doi.org/10.1073/pnas.1113873109
   PubMed Web of Science ®Google Scholar
• Lee JR, Dalton RR, Messina JL, Sharma MD, Smith DM, Burgess RE, Mazzella F, Antonia SJ, Mellor AL, Munn DH. Pattern of recruitment of immunoregulatory antigen-presenting cells in malignant melanoma. Lab Invest 2003; 83:1457-66; PMID:14563947; http://dx.doi.org/10.1097/01.LAB.0000090158.68852.D1
   PubMed Web of Science ®Google Scholar
• Weinlich G, Murr C, Richardsen L, Winkler C, Fuchs D. Decreased serum tryptophan concentration predicts poor prognosis in malignant melanoma patients. Dermatology 2007; 214:8-14; PMID:17191041; http://dx.doi.org/10.1159/000096906
   PubMed Web of Science ®Google Scholar
• Brandacher G, Perathoner A, Ladurner R, Schneeberger S, Obrist P, Winkler C, Werner ER, Werner-Felmayer G, Weiss HG, Gobel G et al. Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin. Cancer Res. 2006; 12:1144-51; PMID:16489067; http://dx.doi.org/10.1158/1078-0432.CCR-05-1966
   PubMed Web of Science ®Google Scholar
• Curti A, Aluigi M, Pandolfi S, Ferri E, Isidori A, Salvestrini V, Durelli I, Horenstein AL, Fiore F, Massaia M et al. Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2,3-dioxygenase. Leukemia 2007; 21:353-5; PMID:17170728; http://dx.doi.org/10.1038/sj.leu.2404485
   PubMed Web of Science ®Google Scholar
• Pan K, Wang H, Chen MS, Zhang HK, Weng DS, Zhou J, Huang W, Li JJ, Song HF, Xia JC. Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 2008; 134:1247-53; PMID:18438685; http://dx.doi.org/10.1007/s00432-008-0395-1
   PubMed Web of Science ®Google Scholar
• Feder-Mengus C, Wyler S, Hudolin T, Ruszat R, Bubendorf L, Chiarugi A, Pittelli M, Weber WP, Bachmann A, Gasser TC et al. High expression of indoleamine 2,3-dioxygenase gene in prostate cancer. Eur. J. Cancer 2008; 44:2266-75; PMID:18619832; http://dx.doi.org/10.1016/j.ejca.2008.05.023
   PubMed Web of Science ®Google Scholar
• Urakawa H, Nishida Y, Nakashima H, Shimoyama Y, Nakamura S, Ishiguro N. Prognostic value of indoleamine 2,3-dioxygenase expression in high grade osteosarcoma. Clin. Exp. Metastasis 2009; 26:1005-12; PMID:19802733; http://dx.doi.org/10.1007/s10585-009-9290-7
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Suda T, Furuhashi K, Suzuki M, Fujie M, Hahimoto D, Nakamura Y, Inui N, Nakamura H, Chida K. Increased serum kynurenine/tryptophan ratio correlates with disease progression in lung cancer. Lung Cancer 2010; 67:361-5; PMID:19487045; http://dx.doi.org/10.1016/j.lungcan.2009.05.001
   PubMed Web of Science ®Google Scholar
• de Jong RA, Nijman HW, Boezen HM, Volmer M, Ten Hoor KA, Krijnen J, van der Zee AG, Hollema H, Kema IP. Serum tryptophan and kynurenine concentrations as parameters for indoleamine 2,3-dioxygenase activity in patients with endometrial, ovarian, and vulvar cancer. Int. J. Gynecol. Cancer 2011; 21:1320-7; PMID:21720257
   PubMed Web of Science ®Google Scholar
• Bonanno G, Mariotti A, Procoli A, Folgiero V, Natale D, De RL, Majolino I, Novarese L, Rocci A, Gambella M et al. Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma. J. Transl. Med. 2012; 10:247; PMID:23232072; http://dx.doi.org/10.1186/1479-5876-10-247
   PubMed Web of Science ®Google Scholar
• Lindstrom V, Aittoniemi J, Jylhava J, Eklund C, Hurme M, Paavonen T, Oja SS, Itala-Remes M, Sinisalo M. Indoleamine 2,3-dioxygenase activity and expression in patients with chronic lymphocytic leukemia. Clin. Lymphoma Myeloma. Leuk. 2012; 12:363-5; PMID:22981691; http://dx.doi.org/10.1016/j.clml.2012.06.001
   PubMed Web of Science ®Google Scholar
• Mitsuka K, Kawataki T, Satoh E, Asahara T, Horikoshi T, Kinouchi H. Expression of indoleamine 2,3-dioxygenase and correlation with pathological malignancy in gliomas. Neurosurgery 2013; 72:1031-8; PMID:23426156; http://dx.doi.org/10.1227/NEU.0b013e31828cf945
   PubMed Web of Science ®Google Scholar
• Choe JY, Yun JY, Jeon YK, Kim SH, Park G, Huh JR, Oh S, Kim JE. Indoleamine 2,3-dioxygenase (IDO) is frequently expressed in stromal cells of Hodgkin lymphoma and is associated with adverse clinical features: a retrospective cohort study. BMC. Cancer 2014; 14:335; PMID:24886161; http://dx.doi.org/10.1186/1471-2407-14-335
   PubMed Web of Science ®Google Scholar
• Ye J, Liu H, Hu Y, Li P, Zhang G, Li Y. Tumoral indoleamine 2,3-dioxygenase expression predicts poor outcome in laryngeal squamous cell carcinoma. Virchows Arch. 2013; 462:73-81; PMID:23179760; http://dx.doi.org/10.1007/s00428-012-1340-x
   PubMed Web of Science ®Google Scholar
• Vonka V. Immunotherapy of chronic myeloid leukemia: present state and future prospects. Immunotherapy. 2010; 2:227-41; PMID:20635930; http://dx.doi.org/10.2217/imt.10.2
   PubMed Web of Science ®Google Scholar
• Vonka V. Comments on therapeutic cancer vaccines. Immunotherapy. 2012; 4:133-5; PMID:22339454; http://dx.doi.org/10.2217/imt.11.173
   PubMed Web of Science ®Google Scholar
• Awad M, Pravica V, Perrey C, El GA, Yonan N, Sinnott PJ, Hutchinson IV. CA repeat allele polymorphism in the first intron of the human interferon-gamma gene is associated with lung allograft fibrosis. Hum. Immunol. 1999; 60:343-6; PMID:10363726; http://dx.doi.org/10.1016/S0198-8859(98)00133-5
   PubMed Web of Science ®Google Scholar
• Sorensen RB, Hadrup SR, Svane IM, Hjortso MC, Thor SP, Andersen MH. Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators. Blood 2011; 117:2200-10; PMID:21079151; http://dx.doi.org/10.1182/blood-2010-06-288498
   PubMed Web of Science ®Google Scholar
• Munir S, Larsen SK, Iversen TZ, Donia M, Klausen TW, Svane IM, Straten PT, Andersen MH. Natural CD4+ T-cell responses against indoleamine 2,3-dioxygenase. PLoS. One. 2012; 7:e34568; PMID:22539948; http://dx.doi.org/10.1371/journal.pone.0034568
   PubMedGoogle Scholar
• Sorensen RB, Kollgaard T, Andersen RS, van den Berg JH, Svane IM, Straten P, Andersen MH. Spontaneous cytotoxic T-Cell reactivity against indoleamine 2,3-dioxygenase-2. Cancer Res. 2011; 71:2038-44; PMID:21406395; http://dx.doi.org/10.1158/0008-5472.CAN-10-3403
   PubMedGoogle Scholar
• Fotopoulou C, Sehouli J, Pschowski R, VON HS, Domanska G, Braicu EI, Fusch G, Reinke P, Schefold JC. Systemic changes of tryptophan catabolites via the indoleamine-2,3-dioxygenase pathway in primary cervical cancer. Anticancer Res. 2011; 31:2629-35; PMID:21778315
   PubMed Web of Science ®Google Scholar
• Bruunsgaard H, Pedersen M, Pedersen BK. Aging and proinflammatory cytokines. Curr. Opin. Hematol. 2001; 8:131-6; PMID:11303144; http://dx.doi.org/10.1097/00062752-200105000-00001
   PubMed Web of Science ®Google Scholar
• Capuron L, Schroecksnadel S, Feart C, Aubert A, Higueret D, Barberger-Gateau P, Laye S, Fuchs D. Chronic low-grade inflammation in elderly persons is associated with altered tryptophan and tyrosine metabolism: role in neuropsychiatric symptoms. Biol. Psychiatry 2011; 70:175-82; PMID:21277567; http://dx.doi.org/10.1016/j.biopsych.2010.12.006
   PubMed Web of Science ®Google Scholar
• Humlova Z, Klamova H, Janatkova I, Sandova P, Sterzl I, Sobotkova E, Hamsikova E, Haskovec C, Pisacka M, Cetkovsky P et al. Immunological profiles of patients with chronic myeloid leukaemia. I. State before the start of treatment. Folia Biol. (Praha) 2006; 52:47-58; PMID:17089915
   PubMed Web of Science ®Google Scholar
• Humlova Z, Klamova H, Janatkova I, Malickova K, Kralikova P, Sterzl I, Roth Z, Hamsikova E, Vonka V. Changes of immunological profiles in patients with chronic myeloid leukemia in the course of treatment. Clin. Dev. Immunol. 2010; 2010:137320; PMID:21197073; http://dx.doi.org/10.1155/2010/137320
   PubMedGoogle Scholar
• Curreli S, Romerio F, Mirandola P, Barion P, Bemis K, Zella D. Human primary CD4 + T cells activated in the presence of IFN-alpha 2b express functional indoleamine 2,3-dioxygenase. J. Interferon Cytokine Res. 2001; 21:431-7; PMID:11440641; http://dx.doi.org/10.1089/107999001750277916
   PubMed Web of Science ®Google Scholar
• Nagai A, Kubota M, Tang L, Adachi S, Usami I, Matsubara K. Hyperuricemia in pediatric malignancies before treatment. Nucleosides Nucleotides Nucleic Acids 2011; 30:1060-5; PMID:22132957; http://dx.doi.org/10.1080/15257770.2011.591745
   PubMed Web of Science ®Google Scholar
• Yamauchi T, Negoro E, Lee S, Takai M, Matsuda Y, Takagi K, Kishi S, Tai K, Hosono N, Tasaki T et al. A high serum uric acid level is associated with poor prognosis in patients with acute myeloid leukemia. Anticancer Res. 2013; 33:3947-51; PMID:24023333
   PubMed Web of Science ®Google Scholar
• Metz R, Rust S, Duhadaway JB, Mautino MR, Munn DH, Vahanian NN, Link CJ, Prendergast GC. IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: a novel IDO effector pathway targeted by D-1-methyl-tryptophan. Oncoimmunology. 2012; 1:1460-8; PMID:23264892; http://dx.doi.org/10.4161/onci.21716
   PubMed Web of Science ®Google Scholar
• Krcmova L, Solichova D, Melichar B, Kasparova M, Plisek J, Sobotka L, Solich P. Determination of neopterin, kynurenine, tryptophan and creatinine in human serum by high throuput HPLC. Talanta 2011; 85:1466-71; PMID:21807211; http://dx.doi.org/10.1016/j.talanta.2011.06.027
   PubMed Web of Science ®Google Scholar